Ebru Tekin Turhan

Patient Access to Pulmolive in China

By  Reinhard Angelmar,  Ebru Tekin Turhan
Add to cart
An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients.

    Published 20 Aug 2021

    Reference 6138

    Topic Marketing

    Industry Pharmaceuticals

    Region Asia

    View case

    Patient Access to Pulmolive in China

    Add to cart
    An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients.
      View case

      Patient Access to Rencell in China

      By  Reinhard Angelmar,  Ebru Tekin Turhan
      Add to cart
      Rencell is a targeted therapy against metastatic renal cell cancer, which significantly prolongs disease-free survival. However, Rencell's international wholesale price of $1,000 for one month of treatment makes the drug unaffordable for many patients in China.

        Published 24 Jun 2013

        Reference 5806

        Topic Marketing

        Industry Pharmaceuticals

        Region Asia

        View case

        Patient Access to Rencell in China

        Add to cart
        Rencell is a targeted therapy against metastatic renal cell cancer, which significantly prolongs disease-free survival. However, Rencell's international wholesale price of $1,000 for one month of treatment makes the drug unaffordable for many patients in China.
          View case